Post doctoral Fellows
Ph.D., China Pharmaceutical University. 2019
姚坤博士毕业于中国药科大学药物化学专业，主要从事计算机辅助的药物设计与合成工作。2022年12月加入龙亚秋课题组，开展博士后研究。
代表性论文：
Kun Yao; Pengyu Liu; Haipeng Liu; Qingyun Wei; Jie Yang; Peng Cao; Yisheng Lai. 3D-QSAR, molecular docking and molecular dynamics simulations study of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives to explore the structure requirements of mutant IDH1 inhibitors, Journal of MolecularStructure, 2019, 1189: 187-202.
Kun Yao; Haipeng Liu; Pengyu Liu; Wenbin Liu; Jie Yang; Qingyun Wei; Peng Cao; Yisheng Lai. Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants, Computational Biology and Chemistry,2020, 86: 107261.
Kun Yao; Hua Liu; Jiajun Yin; Jianmin Yuan; Hong Tao. Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers, Journal of Experimental & Clinical Cancer Research, 2021, 40(1): 263.
Kun Yao; Hua Liu; Shui Yu; Haohao Zhu; Jie Pan. Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies, Cancer Letters, 2022, 533: 215603.
Haohao Zhu; Hui Gao; Yingying Ji; Qin Zhou; Zhiqiang Du; Lin Tian; Ying Jiang; Kun Yao; Zhenhe Zhou. Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials. J Hematol Oncol. 2022 Jul 13;15(1):91.
Kai Wang; Kun Yao; Xuyang Chen; Dake Wen; Yajuan Qin; Zhigang Hu; Yushun Yang. Discovery of the cysteine dynamics during the development and treatment of diabetic process by fluorescent imaging, Redox Biology, 2023, 62.
Chen Cheng; Shimeng Guo; Yuanjun Sun; He Li; Nan Hu; Kun Yao; Huxin Ni; Zhikan Xia; Bin Xu; Xin Xie; Ya-Qiu Long. Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid, European Journal of Medicinal Chemistry, 2023, 251:115267.